technology transfer



  tb vaccine

  leishmaniasis vaccine

  leprosy vaccine


  leishmaniasis diagnostics

  leprosy diagnostics

  chagas diagnostics


  tb drug discovery

  lilly tb drug
  discovery initiative

      about us

      working with us

      approach to IP


Lilly TB Drug Discovery Initiative

About us

The Lilly TB Drug Discovery Initiative (LTI) is a non-profit public-private partnership with a mission to accelerate early-stage drug discovery and to develop clinical candidates by bringing together specialists from around the world for the systematic exploration of vast, private molecular libraries in search of new TB treatments. Headquartered in Seattle, Washington, the Initiative’s goal is to fill the pipeline with new TB drugs.

Founding Members

Eli Lilly and Company
Infectious Disease Research Institute
National Institute for Allergy and Infectious Disease

Initiative Participants

Jubilant Chemsys Limited
RTI International (RTI)
Academia Sinica

1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102  |  P: (206) 381-0883  |  F: (206) 381-3678 © 1993-2016 Privacy Policy
Infectious Disease Research Institute